Achieving WHO recommendations for Hepatitis C Virus Elimination in Belgium
| Journal | Volume 79 - 2016 |
| Issue | Fasc.2 - Original articles |
| Author(s) | Stefan Bourgeois, Sarah Blach, Christian Brixko, Wim Laleman, Catharina Matheï, Jean-Pierre Mulkay, Homie Razavi, Geert Robaeys, Peter Stärkel, Pierre Van Damme, Hans Van Vlierberghe, Dominique Vandijck, Christophe Moreno |
| Full article |
 VIEW FREE PDF |
| (1) ZNA Campus Stuivenberg, Antwerp, Belgium ; (2) Center for Disease Analysis, Louisville, CO. USA ; (3) Department of Gastroenterology and Digestive Oncology, CHR Citadelle, Liege, Belgium ; (4) University Hospitals Leuven, KU Leuven, Leuven, Belgium ; (5) Department of Public Health and Primary Care, University Hospitals Leuven, KU Leuven, Leuven, Belgium ; (6) Hepato-gastroenterology, CHU Saint-Pierre, Brussels, Belgium ; (7) Department of Gastroenterology and Hepatology, Ziekenhuis Oost-Limburg, Genk, Belgium ; (8) Faculty of Medicine and Life Sciences, Hasselt University, Diepenbeek, Belgium ; (9) Department of Hepatology, UZ Leuven, Leuven, Belgium ; (10) Cliniques Universitaires Saint-Luc, Université Catholique de Louvain (UCL), Brussels, Belgium ; (11) Universiteit Antwerpen, Antwerpen, Belgium ; (12) Ghent University Hospital, Ghent, Belgium ; (13) Ghent University, Ghent, Belgium ; (14) Hasselt University, Dept. of Health Economics & Patient Safety, Diepenbeek, Belgium ; (15) CUB Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium. |
|
Background : The World Health Organization (WHO) released updated guidelines for the screening, care and treatment of pa- tients with chronic hepatitis C virus (HCV) infection. Methods : A previously described HCV disease burden model was used to develop a "WHO scenario" to achieve the WHO rec- ommendations of a 90% reduction in incidence and 65% reduction in liver-related deaths. After determining the steps necessary to achieve this goal, the impact of realistic constraints was modeled. Results : In 2015, there were 66.200 viremic infections, with 43% diagnosed and 1.350 treated. In order to reduce new infections, treatment must be extended to = F0 patients, including people who inject drugs and other individuals at risk of transmitting HCV. Additionally, diagnosis and treatment of 3.030 and 4.060 patients, respectively, would be required. The largest attenuation of the WHO scenario would occur if no new cases were diagnosed after 2018 (300% more viremic infections by 2030). Limiting treatment to = F2 patients or treating fewer patients (3.000) would result in 220% or 140% more viremic cases, respectively, compared with the WHO scenario. |
|
© Acta Gastro-Enterologica Belgica. PMID 27382942 |
